Assignee
CRYSTAL PHARMACEUTICAL SUZHOU CO LTD
CN·22 granted patents·20 pending applications·10 citations·filing 2017–2025
Top patents by PatentIndex Score
42 records- 0190US11827630B2Crystal form of lanifibranor, preparation method therefor, and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2022·Granted Nov 28, 2023·1 cites·6 claims
- 0284US10703724B2Crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2017·Granted Jul 7, 2020·3 cites·20 claims
- 0382US11795152B2Crystal form of tafamidis and preparation method therefor and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2021·Granted Oct 24, 2023·1 cites·19 claims
- 0481US11066384B2Crystalline forms of ARN-509, preparation method and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2020·Granted Jul 20, 2021·1 cites·18 claims
- 0580US10759779B2Crystalline form of orexin receptor antagonist, processes for preparation thereof and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2020·Granted Sep 1, 2020·1 cites·8 claims
- 0676US10752595B2Crystalline forms of a bromodomain and extraterminal protein inhibitor drug, processes for preparation thereof, and use thereofCRYSTAL PHARMACEUTICAL (SUZHOU) CO LTD·Filed 2017·Granted Aug 25, 2020·1 cites·22 claims
- 0775US11339158B2Crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2018·Granted May 24, 2022·1 cites·7 claims
- 0875US10604528B2Galunisertib crystalline form, preparation method thereof and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2017·Granted Mar 31, 2020·1 cites·4 claims
- 0973US2024092771A1Crystal form of lanifibranor, preparation method therefor, and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2023·Application pending·0 cites
- 1066US2025382286A1Co-crystal of aficamten, and preparation method therefor and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2025·Application pending·0 cites
- 1164US11572365B2Crystal form of upadacitinib, preparation method therefor, and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2022·Granted Feb 7, 2023·0 cites·16 claims
- 1260US2022324808A1Co-crystal of Compound I Dihydrochloride and Preparation Method and Use ThereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 1358US11149004B2Crystalline form of EB-1020, processes for preparation and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2018·Granted Oct 19, 2021·0 cites·10 claims
- 1458US11091494B2Crystal form of acalabrutinib and preparation method and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2018·Granted Aug 17, 2021·0 cites·14 claims
- 1558US10604521B2Crystalline forms of PLX3397 hydrochloride, processes for preparation and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2017·Granted Mar 31, 2020·0 cites·6 claims
- 1658US2025042866A1Crystal form of blarcamesine hydrochloride, method for preparing same, and use therofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2024·Application pending·0 cites
- 1758US2022267326A1Crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 1857US12428402B2Resmetirom crystal, preparation method for same, and uses thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2022·Granted Sep 30, 2025·0 cites·9 claims
- 1957US10442800B2Crystal forms of NBI-98854, preparation method and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2017·Granted Oct 15, 2019·0 cites·14 claims
- 2056US12595254B2Crystal form of Resmetirom, preparation method therefor, and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2021·Granted Apr 7, 2026·0 cites·10 claims
- 2156US11136347B2Crystalline forms of a fatty acid bile acid conjugate, preparation method thereof and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2018·Granted Oct 5, 2021·0 cites·19 claims
- 2256US10815232B2Crystalline forms of viral-protein inhibitor drug VX-787, processes for preparation thereof and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2018·Granted Oct 27, 2020·0 cites·19 claims
- 2355US12162885B2Crystal form of Xevinapant for treating LA SCCHNCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2024·Granted Dec 10, 2024·0 cites·10 claims
- 2455US11124517B2Crystal form of Baricitinib and preparation method thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2018·Granted Sep 21, 2021·0 cites·9 claims
- 2555US2024425460A1Crystal form of nirogacestat dihydrobromide, and preparation method therefor, and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2024·Application pending·0 cites
- 2653US10815221B2Crystal forms of an androgen receptor antagonist, preparation method and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2017·Granted Oct 27, 2020·0 cites·14 claims
- 2753US10633376B2Crystalline forms of JAK1-selective inhibitor, processes for preparation and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2017·Granted Apr 28, 2020·0 cites·21 claims
- 2853US10626135B2Crystal forms of sodium-glucose co-transporter inhibitor, processes for preparation and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2017·Granted Apr 21, 2020·0 cites·5 claims
- 2952US2023039086A1Bms-986165 crystal form, preparation method therefor and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2020·Application pending·0 cites
- 3052US2023049130A1Deucravacitinib crystal form, preparation method therefor and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2020·Application pending·0 cites
- 3152US2021300893A1Crystalline forms of arn-509, preparation method and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 3251US2025145588A1Crystal form of tavapadon, and preparation method therefor and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2023·Application pending·0 cites
- 3350US2022251044A1Crystal form of hypoxia-inducible factor-prolyl hydroxylase inhibitorCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 3449US2020270226A1Crystalline forms of arn-509, preparation method and use thereofCRYSTAL PHARMACEUTICAL (SUZHOU) CO LTD·Filed 2019·Application pending·0 cites
- 3549US2025282711A1Crystalline form of elacestrant and preparation method and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2023·Application pending·0 cites
- 3646US2022002306A1Crystal form of upadacitinib and preparation method and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2019·Application pending·0 cites
- 3746US2021332014A1Cabozantinib malate crystal form, preparation method and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2019·Application pending·0 cites
- 3845US2021171568A1Crystalline forms of selective progesterone receptor modulator, processes for preparation thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2018·Application pending·0 cites
- 3945US2021380596A1Upadacitinib crystal form and preparation method therefor and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2020·Application pending·0 cites
- 4044US2024343723A1Crystal form of lanifibranor, preparation method therefor, and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 4144US2021087195A1New crystal form of acalbrutinib, preparation method therefor and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2019·Application pending·0 cites
- 4242US2021363101A1Crystalline forms of gft-505, processes for preparation and use thereofCRYSTAL PHARMACEUTICAL SUZHOU CO LTD·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when CRYSTAL PHARMACEUTICAL SUZHOU CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →